SOLFA Study to Explore the Thrombogenicity of a Dialyzer

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 17, 2022

Primary Completion Date

February 10, 2022

Study Completion Date

May 20, 2023

Conditions
End Stage Renal Disease on Dialysis
Interventions
DEVICE

Compared the trombogenicity of the Solacea dialyzer with synthetic dialyzers after progressively decreasing heparin until discontinuing it

The duration of the study was four weeks, carried out in two phases. After screening, patients were randomized to be dialyzed with the Solacea™ hemodialyzer versus the usual hemodialyzer, which in all cases had to be a synthetic membrane. In both arms, heparin was progressively decreased until it was discontinued. Afterwards the patients were crossed over to the other arm.

Trial Locations (1)

28031

Hospital Universitario Infanta Leonor, Madrid

All Listed Sponsors
lead

Fundación Senefro

OTHER